Global Anti-Obesity Drugs Market - ABC6 - Providence, RI and New Bedford, MA News, Weather

Global Anti-Obesity Drugs Market

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, July 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Anti-Obesity Drugs Market

http://www.reportlinker.com/p0109903/Global-Anti-Obesity-Drugs-Market.html

This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -

 

Arena Pharmaceuticals, Inc.

GlaxoSmithKline Plc

Novo Nordisk

Orexigen Therapeutics, Inc.

Rhythm Pharmaceuticals

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

 

1. INDUSTRY OVERVIEW II-1

Anti-Obesity Therapeutics - A Significantly Underserved Market II-1

Obesity: An Unmet Medical Need II-2

Currently Available Drugs II-2

List of Currently Available Drugs for the Treatment of Obesity II-3

The United States - The Largest Obesity and Anti-Obesity Market II-4

Europe - A Market with Vast Potential II-4

Emerging Economies to Lead Growth II-4

Table 1: Global Obesity Prevalence (2013): Percentage Share

Breakdown of Obese Population by Leading Countries (includes

corresponding Graph/Chart) II-5

 

2. COMPETITIVE SCENARIO II-6

Drug Withdrawals Alter Competition Metrics II-6

Unfavorable Reimbursement Levels Hamper Growth II-6

New Entrants to Induce Competition II-7

Anti-Obesity Drugs Under Pipeline II-7

 

3. MARKET TRENDS, DRIVERS AND CHALLENGES II-8

Alarming Rise in Global Obesity Levels - The Major Growth Factor II-8

Table 2: Classification of BMI II-9

Table 3: Overweight and Obese Population (Millions) for 2013

in Select Geographic Regions (includes corresponding

Graph/Chart) II-9

 

Table 4: Global Obesity Levels by Leading Countries and

Others (2013): Percentage Breakdown of Obese Population for

the United States, India, China, Mexico, the United Kingdom,

Germany, Spain, Australia, Canada, Japan, Greece, South

Korea, Portugal, Slovakia, New Zealand, Finland, Switzerland,

Ireland, and Others (includes corresponding Graph/Chart) II-9

 

Table 5: Abdominal Obesity Prevalence (%) by Region and

Gender (includes corresponding Graph/Chart) II-10

Growing Emphasis on Metabolism II-10

New Research Aids in Discovery of Novel Drugs II-10

Cyclic Guanosine Monophosphate Signaling - The Future of Anti-

Obesity Pharmacotherapy? II-10

Childhood Obesity - A Market with Unmet Needs II-11

Online Drug Stores Boost Sales II-11

Barriers to Development of Effective Drugs II-12

Regulatory Additions - A Barrier to Entry? II-12

High Drug Development Costs - A Major Setback II-12

Weight Loss Alternatives - A Market Dampener II-13

Short Treatment Duration - A Major Limiting Factor for Market

Growth II-13

Product Labelling Could Deter Treatment Continuation II-13

 

4. SELECT PIPELINE DRUG CANDIDATES II-14

Orexigen Completes Phase 3 Clinical Trials for NB32 II-14

Empatic™ Completes Phase II II-14

Zafgen Completes Phase II Trial of Beloranib II-14

Novo Nordisk Completes Phase III trial of Liraglutide II-14

Rhythm Pharmaceuticals Commences Phase 2 Trials for RM 493 II-14

University of Michigan to Commence Trial of Amlexanox in

Treating Obesity II-15

 

5. SELECT SCIENTIFIC BREAKTHROUGHS II-16

Study Links PAR2 Protein Amount to Obesity II-16

Scientists at Cambridge University Discover Hunger Gene II-16

Ghrelin Hormone Linked to Hunger and Obesity II-16

 

6. OBESITY - AN INTRODUCTION II-17

Diagnosis of Obesity II-17

BMI Calculation and Classification II-17

Waist Circumference and BMI II-17

Types of Obesity II-18

Monogenic Obesity II-18

Polygenic Obesity II-18

Causes of Obesity II-18

Unhealthy Eating Habits II-18

Environmental and Genetic Factors II-18

Sedentary Lifestyle II-19

Alcohol Intake II-19

Childhood Obesity II-19

Psychological Factors II-19

Pregnancy II-19

Hormonal Disorders II-19

Drugs II-19

Aging II-20

Risks Associated with Obesity II-20

 

7. OBESITY TREATMENT II-21

Dietary Therapy II-21

Exercise Therapy II-21

Behavior Therapy II-21

Pharmacotherapy II-21

Weight Loss Surgery II-21

Invasive Vis-à-vis Non-invasive Procedures II-21

A Brief Review of Select Invasive Procedures II-22

Bariatric Surgery II-22

Laparoscopic Adjustable Gastric Banding (LAGB) II-22

Vertical Banded Gastroplasty (VBG) II-22

Roux-en-Y Gastric Bypass Procedure (RYGB) II-22

Lap-Band Procedure II-22

Gastric Band Procedure II-22

Gastric Bypass Procedure II-22

Doudenal Switch II-22

Prescription Drugs Vis-à-vis Non-Prescription Drugs II-23

Table 6: Obesity Treatment Options and Corresponding Success

Rate II-23

 

8. ANTI-OBESITY DRUGS - AN INSIGHT II-24

Introduction II-24

Mechanism of Action II-24

Review of Available Prescription Anti-Obesity Drugs II-25

Phentermine II-25

Orlistat II-25

Belviq (Lorcaserin) II-25

Phentermine/Topiramate Cocktail II-26

Table 7: Global Anti-obesity Prescription Drugs Market

(2012): Percentage Share Breakdown of Prescriptions by

Physician Practices - Primary Care Physicians (PCP),

Internal Medicine, Obstetrics/Gynecology,

Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology and

Others (includes corresponding Graph/Chart) II-26

 

9. RECENT INDUSTRY ACTIVITY II-27

Novo Nordisk to Launch Anti-Obesity Drug in Mexico II-27

Orexigen Optimistic of FDA Approval for Contrave II-27

Arena Extends Belviq Distribution Agreement with Eisai II-27

Sorrento Partners Scripps Research II-27

MedImmune Partners NGM Biopharmaceuticals to Develop Anti-

Obesity Therapy II-27

Arena Launches Belviq II-27

Kitozyme Signs Deal with Corona II-28

GSK and Vanderbilt Sign Agreement for New Anti-Obesity Drug II-28

ScinoPharm Signs Agreement for Contract Manufacturing II-28

Vivus Launches Qsymis II-28

ScinoPharm Enters Supply Deal with Vivus II-28

 

10. FOCUS ON SELECT PLAYERS II-29

Arena Pharmaceuticals, Inc. (US) II-29

F. HOFFMANN-LA ROCHE LTD. (Switzerland) II-29

GlaxoSmithKline Plc. (UK) II-30

Novo Nordisk (Denmark) II-30

Orexigen Therapeutics, Inc. (US) II-30

Rhythm Pharmaceuticals (US) II-31

VIVUS, Inc. (US) II-31

Zafgen Inc. (US) II-31

 

11. GLOBAL MARKET PERSPECTIVE II-32

Table 8: World Recent Past, Current & Future Analysis for

Anti-Obesity Drugs by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2013 through 2020 (includes

corresponding Graph/Chart) II-32

 

Table 9: World Historic Review for Anti-Obesity Drugs by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(Excl. Japan), Latin America and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2012 (includes corresponding

Graph/Chart) II-33

 

Table 10: World 15-Year Perspective for Anti-Obesity Drugs by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin

America and Rest of World Markets for Years 2006, 2014 and

2020 (includes corresponding Graph/Chart) II-34

III. MARKET

 

1. THE UNITED STATES III-1

A.Market Analysis III-1

Table 11: US Weight Loss Market by Major Product Segment

(2013): Percentage Share Breakdown of Revenues for Diet

Drinks, Health Clubs, Bariatric Surgery, Diet Foods,

Artificial Sweeteners, Weight Loss Centers, Medically

Supervised Programs, Meal Replacements & Appetite

Suppressants, Prescription Drugs, Low Calorie Diet Programs,

and Others (includes corresponding Graph/Chart) III-1

Competitive Scenario III-2

Obesity Catching Them Young III-2

Table 12: US Childhood Obesity by Age-Group (2013):

Percentage of Obese Population (includes corresponding

Graph/Chart) III-2

Penetration of Anti-Obesity Drugs Remains Poor III-3

Key Statistics III-3

Table 13: US Obesity Rates by Ethnicity for Men & Women:

2013 (includes corresponding Graph/Chart) III-3

 

Table 14: Proportion (%) of Obesity in the US Overweight

Population by Age Group (includes corresponding

Graph/Chart) III-3

 

Table 15: Obesity Prevalence in US Adults by Type (2013)

(includes corresponding Graph/Chart) III-4

 

Table 16: US Obesity Prevalence by Age-group: 2013

(includes corresponding Graph/Chart) III-4

 

Table 17: US Obesity Prevalence by Annual Income Level

(%): 2013 (includes corresponding Graph/Chart) III-4

State-wise Stats III-5

Table 18: US Obesity Prevalence by Top Cities (% of Total

Population): 2013 (includes corresponding Graph/Chart) III-6

 

Table 19: US Prevalence of Obesity by Top States (% of

Total Population): 2013 (includes corresponding

Graph/Chart) III-6

Reimbursement Scenario III-7

Regulatory Environment III-7

High Development Costs - A High Entry Barrier for Drug Makers III-8

Lack of Overall efficacy and outcomes data - A Dampener III-8

Obesity and Related Ailments: Burden on Societal and

Economic Costs III-8

Product Launches III-9

Strategic Corporate Developments III-9

Select Key Players III-10

B.Market Analytics III-11

Table 20: The US Recent Past, Current & Future Analysis for

Anti-Obesity Drugs Market Analyzed with Annual Sales Figures

in US$ Million for Years 2013 through 2020 (includes

corresponding Graph/Chart) III-11

 

Table 21: The US Historic Review for Anti-Obesity Drugs

Market Analyzed with Annual Sales Figures in US$ Million for

Years 2006 through 2012 (includes corresponding Graph/Chart) III-12

 

2. CANADA III-13

Market Analysis III-13

Table 22: Canadian Recent Past, Current & Future Analysis

for Anti-Obesity Drugs Market Analyzed with Annual Sales

Figures in US$ Million for Years 2013 through 2020 (includes

corresponding Graph/Chart) III-13

 

Table 23: Canadian Historic Review for Anti-Obesity Drugs

Market Analyzed with Annual Sales Figures in US$ Million for

Years 2006 through 2012 (includes corresponding Graph/Chart) III-14

 

3. JAPAN III-15

Market Analysis III-15

Table 24: Japanese Recent Past, Current & Future Analysis

for Anti-Obesity Drugs Market Analyzed with Annual Sales

Figures in US$ Million for Years 2013 through 2020 (includes

corresponding Graph/Chart) III-15

 

Table 25: Japanese Historic Review for Anti-Obesity Drugs

Market Analyzed with Annual Sales Figures in US$ Million for

Years 2006 through 2012 (includes corresponding Graph/Chart) III-16

 

4. EUROPE III-17

A.Market Analysis III-17

Europe - an Opportune Market for Chronic Weight Management

Drugs III-17

Prevalence of Obesity in Europe III-17

Table 26: Obese and Overweight & Obese Population in the

European Union (2013): Percentage Share Breakdown by Age

Group (includes corresponding Graph/Chart) III-18

 

Table 27: Select EU Member Countries Ranked by Obesity

Rates (2013): Percentage Share of Domestic Obese Population

in Global Obese Population (includes corresponding

Graph/Chart) III-18

 

Table 28: Obesity Prevalence in Select EU Countries (2013)

by Gender (%) (includes corresponding Graph/Chart) III-19

B.Market Analytics III-20

Table 29: European Recent Past, Current & Future Analysis

for Anti-Obesity Drugs by Geographic Region/Country -

France, Germany, Italy, UK and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2013 through 2020 (includes corresponding

Graph/Chart) III-20

 

Table 30: European Historic Review for Anti-Obesity Drugs by

Geographic Region/Country - France, Germany, Italy, UK and

Rest of Europe Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2006 through 2012

(includes corresponding Graph/Chart) III-21

 

Table 31: European 15-Year Perspective for Anti-Obesity

Drugs by Geographic Region/ Country - Percentage Breakdown

of Dollar Sales for France, Germany, Italy, UK and Rest of

Europe Markets for Years 2006, 2014 and 2020 (includes

corresponding Graph/Chart) III-22

 

4a. FRANCE III-23

A.Market Analysis III-23

Changing Lifestyle Alters Health Profile III-23

B.Market Analytics III-24

Table 32: French Recent Past, Current & Future Analysis for

Anti-Obesity Drugs Market Analyzed with Annual Sales Figures

in US$ Million for Years 2013 through 2020 (includes

corresponding Graph/Chart) III-24

 

Table 33: French Historic Review for Anti-Obesity Drugs

Market Analyzed with Annual Sales Figures in US$ Million for

Years 2006 through 2012 (includes corresponding Graph/Chart) III-25

 

4b. GERMANY III-26

A.Market Analysis III-26

The Largest Anti-Obesity Market in Europe III-26

B.Market Analytics III-26

Table 34: German Recent Past, Current & Future Analysis for

Anti-Obesity Drugs Market Analyzed with Annual Sales Figures

in US$ Million for Years 2013 through 2020 (includes

corresponding Graph/Chart) III-26

 

Table 35: German Historic Review for Anti-Obesity Drugs

Market Analyzed with Annual Sales Figures in US$ Million for

Years 2006 through 2012 (includes corresponding Graph/Chart) III-27

 

4c. ITALY III-28

Market Analysis III-28

Table 36: Italian Recent Past, Current & Future Analysis for

Anti-Obesity Drugs Market Analyzed with Annual Sales Figures

in US$ Million for Years 2013 through 2020 (includes

corresponding Graph/Chart) III-28

 

Table 37: Italian Historic Review for Anti-Obesity Drugs

Market Analyzed with Annual Sales Figures in US$ Million for

Years 2006 through 2012 (includes corresponding Graph/Chart) III-29

 

4d. THE UNITED KINGDOM III-30

A.Market Analysis III-30

Anti-Obesity Drugs - the Need of the Hour as NHS Firefights

Rising Peril of Obesity III-30

GlaxoSmithKline Plc - A Key Player III-30

Strategic Corporate Development III-31

B.Market Analytics III-32

Table 38: The UK Recent Past, Current & Future Analysis for

Anti-Obesity Drugs Market Analyzed with Annual Sales Figures

in US$ Million for Years 2013 through 2020 (includes

corresponding Graph/Chart) III-32

 

Table 39: The UK Historic Review for Anti-Obesity Drugs

Market Analyzed with Annual Sales Figures in US$ Million for

Years 2006 through 2012 (includes corresponding Graph/Chart) III-33

 

4e. REST OF EUROPE III-34

A.Market Analysis III-34

Review of Select Markets III-34

Spain III-34

Belgium III-34

The Netherlands III-34

Finland III-34

Sweden III-35

Strategic Corporate Development III-35

Key Players III-35

B.Market Analytics III-37

Table 40: Rest of European Recent Past, Current & Future

Analysis for Anti-Obesity Drugs Market Analyzed with Annual

Sales Figures in US$ Million for Years 2013 through 2020

(includes corresponding Graph/Chart) III-37

 

Table 41: Rest of European Historic Review for Anti-Obesity

Drugs Market Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-38

 

5. ASIA-PACIFIC III-39

A.Market Analysis III-39

Brief Review of Select Countries III-39

Australia III-39

Table 42: Australian Obesity & Overweight Prevalence

(2013): Percentage Share Breakdown of Population for

Obese/Overweight, Healthy Weight and Underweight

Categories (includes corresponding Graph/Chart) III-39

Historic Perspective: III-40

Table 43: Prevalence Rate (%) of Overweight/Obese

Students in Australia (includes corresponding

Graph/Chart) III-40

China III-40

India III-41

Korea III-41

Use of Diet Pills Lack Proper Monitoring III-41

New Zealand III-41

Strategic Corporate Developments III-41

B.Market Analytics III-42

Table 44: Asia-Pacific Recent Past, Current & Future

Analysis for Anti-Obesity Drugs Market Analyzed with Annual

Sales Figures in US$ Million for Years 2013 through 2020

(includes corresponding Graph/Chart) III-42

 

Table 45: Asia-Pacific Historic Review for Anti-Obesity

Drugs Market Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-43

 

6. LATIN AMERICA III-44

A.Market Analysis III-44

Mexico - A Review III-44

B.Market Analytics III-45

Table 46: Latin American Recent Past, Current & Future

Analysis for Anti-Obesity Drugs Market Analyzed with Annual

Sales Figures in US$ Million for Years 2013 through 2020

(includes corresponding Graph/Chart) III-45

 

Table 47: Latin American Historic Review for Anti-Obesity

Drugs Market Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-46

 

7. REST OF WORLD III-47

Market Analysis III-47

Table 48: Rest of World Recent Past, Current & Future

Analysis for Anti-Obesity Drugs Market Analyzed with Annual

Sales Figures in US$ Million for Years 2013 through 2020

(includes corresponding Graph/Chart) III-47

 

Table 49: Rest of World Historic Review for Anti-Obesity

Drugs Market Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2012 (includes corresponding

Graph/Chart) III-48

IV. COMPETITIVE LANDSCAPE

 

Total Companies Profiled: 33 (including Divisions/Subsidiaries - 34)

 

The United States (14)

Japan (4)

Europe (8)

- The United Kingdom (3)

- Rest of Europe (5)

Asia-Pacific (Excluding Japan) (8)

To order this report: Global Anti-Obesity Drugs Market

http://www.reportlinker.com/p0109903/Global-Anti-Obesity-Drugs-Market.html

 

 

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

10 Orms Street Providence, R.I. 02904
401-453-8000

All content © Copyright 2000 - 2014 WorldNow and WLNE.
All Rights Reserved.

For more information on this site, please read our Privacy Policy and Terms of Service.